S100A1 and pulmonary arterial hypertension: The therapeutic potential of S100A1 in PAH was demonstrated by the administration of exogenous S100A1 to S100A1 knockout (KO) mice, leading to improvements in pulmonary artery pressure, vascular resistance, and endothelial cell survival (73).